Jingquan Jia, Ph.D.
Affiliations: | 2008 | Duke University, Durham, NC |
Area:
Molecular Biology, Cell Biology, GeneticsGoogle:
"Jingquan Jia"Parents
Sign in to add mentor| Michael Krangel | grad student | 2008 | Duke | |
| (The activation of TCR Vbeta8.2 gene germline transcription.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ding S, Hsu C, Wang Z, et al. (2022) Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell |
| Jia J, Howard L, Liu Y, et al. (2022) Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemotherapy and Pharmacology |
| Jia J, Niedzwiecki D, Arrowood C, et al. (2020) A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA. Journal of Clinical Oncology. 38 |
| Goyal L, Lamarca A, Strickler JH, et al. (2020) The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal of Clinical Oncology. 38: e16686-e16686 |
| Mettu NB, Niedzwiecki D, Rushing C, et al. (2019) A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Cancer Chemotherapy and Pharmacology |
| Jia J, Morse MA, Nagy RJ, et al. (2018) Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Frontiers in Oncology. 8: 305 |
| Vlahovic G, Meadows KL, Hatch AJ, et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. The Oncologist |
| Jia J, Niedzwiecki D, Uronis HE, et al. (2018) A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood. Journal of Clinical Oncology. 36: 3555-3555 |
| Hatch AJ, Sibley AB, Starr MD, et al. (2016) Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Medicine |
| Jia J, Dellinger AE, Weiss ES, et al. (2015) Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |